

Critically Important Antimicrobials for Human Medicine

2nd Revision



**World Health
Organization**

**WHO Advisory Group on Integrated Surveillance
of Antimicrobial Resistance (AGISAR)**

**Critically Important
Antimicrobials
for Human Medicine**

2nd Revision



Department of Food Safety and Zoonoses

WHO Library Cataloguing-in-Publication Data

Critically important antimicrobials for human medicine - 2nd rev.

1.Anti-infective agents - classification. 2.Anti-infective agents - adverse effects. 3.Drug resistance, microbial - drug effects.
4.Risk management. 5.Humans. I.World Health Organization.

ISBN 978 92 4 150143 9 (NLM classification: QV 250)

© World Health Organization 2011

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed by the WHO Document Production Services, Geneva, Switzerland

CONTENTS

| | |
|----------------------------------------------------------------------------------------------------------------------|----|
| 1. History of the current document | 1 |
| 2. What should the list be used for? | 1 |
| 3. What should the list NOT be used for? | 2 |
| 4. The criteria | 2 |
| 5. Interpretation of categorization | 3 |
| Table 1. Listing and categorization of antimicrobials used in human medicine | 4 |
| 6. Prioritization within the Critically Important category | 11 |
| Table 2. Prioritization of antimicrobials categorized as <i>Critically Important</i> in human medicine | 13 |
| 7. The top three Critically Important Antimicrobials | 18 |

1. History of the current document

The 1st WHO Expert Meeting on Critically Important Antimicrobials (CIA) for Human Health was held in Canberra, Australia, in 2005. During this meeting, participants considered the list of all antimicrobial classes used in human medicine and categorized antimicrobials into three groups of *critically important*, *highly important*, and *important* based on criteria developed.

The 2nd WHO Expert Meeting on Critically Important Antimicrobials for Human Health was held in Copenhagen, Denmark, in May 2007. In this meeting, participants reviewed the two criteria and re-examined the categorization of all human antibacterial classes in light of new drug development and scientific information since 2005. Participants were also requested to prioritize agents within the critically important category in order to allow allocation of resources on the agents for which management of the risks from antimicrobial resistance are needed most urgently.

The 1st AGISAR meeting held in Copenhagen, 2009 was a follow-up of these two previous expert consultations. Experts from the meeting reviewed the Copenhagen 2007 list of CIA (1st revision of the CIA list) and came up with the 2nd revision of the WHO list of critically important antimicrobials for human medicine, taking into account new scientific information and new drugs.

2. What should the list be used for?

The list of Critically Important Antimicrobials can be used as a reference to help formulate and prioritize risk assessment and risk management strategies for containing antimicrobial resistance due to non-human antimicrobial use. Specific examples include:

- Prioritization of the antimicrobials characterized as *critically important* for most urgent development of risk management strategies in order to preserve their effectiveness in human medicine.
- Elevating the categorization of specific antimicrobials in regions/countries where it is warranted
- Designing antimicrobial susceptibility testing platforms for use in national programmes to monitor antimicrobial resistance

- Informing national policies related to antimicrobial resistance
- Developing appropriate new drugs and vaccines that will preserve critically important antimicrobial agents

3. What should the list NOT be used for?

- As the sole source of information for developing risk management strategies.
- As the sole source of treatment guidelines for either animals or humans.
- To minimize the importance of other critically important antimicrobials in the same category.

4. The criteria

Criterion 1:

Antimicrobial agent is used as sole therapy or one of few alternatives to treat serious human disease.

Explanation: It is self-evident that antimicrobials that are the sole or one of few alternatives for treatment of serious infectious diseases in humans have an important place in human medicine. Serious disease refers to those illnesses which, if left untreated, are likely to result in irreversible morbidity or mortality. Seriousness of disease may relate to the site of infection or the host (e.g. pneumonia, meningitis). Multidrug resistance alone may or may not influence patient outcomes. For instance, multidrug resistance in *S. aureus* limits options in the treatment of pneumonia, but incision and drainage alone appears effective without antimicrobials in the treatment of skin abscesses. Therefore drug resistance does not influence the treatment of patient

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_28796

